03:21 , Nov 17, 2018 |  BioCentury  |  Product Development

Betting Combos on Biomarkers

Despite lackluster monotherapy data at SITC from the latest tranche of immunotherapy candidates, drug developers are moving into combination trials with PD-1 and PD-L1 inhibitors based on biomarkers of pharmacodynamic activity. Results from the next...
13:02 , Nov 6, 2018 |  BC Extra  |  Preclinical News

Codiak’s exosomes could offer new tack to STING agonism

Exosome company Codiak BioSciences Inc. (Cambridge, Mass.) on Tuesday provided a first glimpse of preclinical data for its exoSTING program, with a therapy that is among the next generation of STING agonists that go beyond...
16:47 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Latest immuno-oncology monotherapy data continue to cast doubt on combo strategies

New data for next generation immuno-oncology agents add to the debate of whether and how agents that show no efficacy as monotherapies in Phase I trials should be advanced to later stage combination trials. Merck...
01:10 , Oct 22, 2018 |  BC Extra  |  Clinical News

Latest immuno-oncology monotherapy data continue to cast doubt on combo strategies

New data for next generation immuno-oncology agents add to the debate of whether and how agents that show no efficacy as monotherapies in Phase I trials should be advanced to later stage combination trials. This...
23:27 , Jun 14, 2018 |  BC Innovations  |  Tools & Techniques

Imaging immunotherapy

Stanford University researchers have made an imaging agent that detects activated T cells and could predict whether a patient will respond to immunotherapy within days of treatment. Typically, it takes weeks to months to determine...
18:06 , May 15, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Mouse studies suggest a fusion protein-based vaccine plus a STING-activating cyclic dinucleotide (CDN) adjuvant could help prevent tuberculosis (TB). The fusion protein consists of five Mycobacterium tuberculosis antigens: fbpB, esxA, hrp1, rpfD and...
14:10 , Apr 3, 2018 |  BC Innovations  |  Targets & Mechanisms

Sensor sensibility

Zhijian “James” Chen’s discovery of the DNA sensor cGAS revealed the missing link between cytosolic DNA and innate immune activation, paving the way for immunotherapies targeting the cGAS-STING pathway. The lowest-hanging fruit has been in...
01:24 , Jan 18, 2018 |  BC Extra  |  Preclinical News

Chromosomal instability can trigger metastasis via STING activity

A paper published in Nature brings into question the safety and efficacy of activating the transmembrane protein 173 (STING; TMEM173) pathway -- which triggers immune responses in the presence of cytosolic DNA -- in cancers...
02:05 , Dec 14, 2017 |  BC Week In Review  |  Clinical News

Aduro discontinues development of CRS-207

Aduro Biotech Inc. (NASDAQ:ADRO) said it will discontinue development of CRS-207 based on "insufficient clinical activity" in Phase I/II trials of the candidate to treat mesothelioma and ovarian cancer. Aduro said it will now focus...
00:09 , Dec 13, 2017 |  BC Extra  |  Clinical News

Aduro discontinues development of CRS-207

Aduro Biotech Inc. (NASDAQ:ADRO) said it will discontinue development of CRS-207 based on "insufficient clinical activity" in Phase I/II trials of the candidate to treat mesothelioma and ovarian cancer. Aduro said it will now focus...